Business Context and Reporting Period
Zymeworks Inc. (ZYME) is a global biotechnology company focused on a royalty-driven asset aggregation strategy, managing a portfolio of licensed healthcare assets and developing novel biotherapeutics. This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates as a single reporting segment and is classified as a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $2.4 million | $27.1 million |
| Net Loss | $(44.2) million | $(22.6) million |
| Loss Per Share (Diluted) | $(0.59) | $(0.30) |
| Operating Expenses | $49.5 million | $52.7 million |
| Cash and Cash Equivalents | $244.3 million | $41.2 million (Dec 31, 2025) |
| Total Liquidity (Cash + Marketable Securities) | $403.8 million | $270.6 million (Dec 31, 2025) |
| Liability: Sale of Future Royalties | $246.5 million | $0 |
Note: Revenue consists primarily of collaboration revenue, including royalties from Ziihera (zanidatamab-hrii) sales by partners Jazz Pharmaceuticals and BeOne Medicines.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 91% ($24.7 million) compared to Q1 2025. This was driven by the absence of non-recurring milestone payments received in Q1 2025 from GSK ($14.0 million) and Daiichi Sankyo ($3.1 million), and a decline in development support revenue from Jazz as clinical responsibilities transitioned to the partner. This was partially offset by increased royalty revenue from Ziihera sales.
- Net Loss Expansion: Net loss increased to $44.2 million from $22.6 million. The increase was primarily due to $2.1 million in interest expense related to a new royalty monetization transaction and a reduction in interest income due to lower cash balances prior to the financing event.
- Liquidity Surge: Cash and cash equivalents increased significantly from $41.2 million at year-end 2025 to $244.3 million at March 31, 2026. This was driven by net proceeds of approximately $245.6 million from a royalty sale agreement with Royalty Pharma.
- Share Repurchases: The company repurchased 3.2 million shares for $76.2 million under its 2025 Repurchase Program during the quarter.
Guidance, Outlook, and Management Commentary
- Royalty Monetization: In March 2026, Zymeworks entered into a sale agreement with Royalty Pharma to monetize 30% of future royalties from Ziihera. The company received a $250 million non-recourse term loan, recorded as a liability. The company retains 70% of royalties and all milestone payments. The estimated effective interest rate is 10.3%.
- Strategic Focus: Management emphasizes a strategy of disciplined capital allocation, focusing on royalty growth, strategic acquisitions, and internal innovation. The company expects to fund operations for at least the next 12 months with existing cash resources.
- Pipeline Updates:
- Ziihera: Partners Jazz and BeOne have submitted sBLAs for first-line HER2+ gastroesophageal adenocarcinoma (GEA) in the U.S. and China. The FDA accepted the U.S. filing for priority review with a PDUFA date of August 25, 2026. Potential near-term milestones total $440 million upon approvals in the U.S., EU, Japan, and China.
- ZW191: Received FDA Fast Track designation for platinum-resistant ovarian cancer. Phase 1 dose optimization is ongoing.
- ZW251: Phase 1 recruitment is ongoing for hepatocellular carcinoma (HCC).
- ZW220: Preparations for Phase 1 have been paused to prioritize ZW251.
- Risks: Key risks include the unproven nature of the royalty aggregation strategy, dependence on strategic partners (Jazz, BeOne, J&J) for development and commercialization, regulatory approval uncertainties, and potential impacts of trade tariffs and geopolitical tensions on supply chains.
Investor Verification Checklist
- Royalty Sale Terms: Verify the specific covenants and repayment triggers in the Royalty Pharma Loan Agreement, particularly regarding events of default such as termination of the Jazz or BeOne agreements.
- Ziihera Regulatory Timeline: Monitor the August 25, 2026 PDUFA date for the U.S. sBLA and the status of the China NMPA filing for GEA approval, as these drive significant milestone revenue.
- Operating Cash Flow: Assess the sustainability of the $45.7 million cash burn from operations in Q1 2026 against the $403.8 million liquidity runway.
- Share Count Reduction: Track the remaining capacity ($37.3 million as of March 31, 2026) under the 2025 Repurchase Program and its impact on diluted earnings per share.
- Partnership Performance: Review quarterly updates from Jazz and BeOne regarding Ziihera commercial sales volumes to validate royalty revenue projections.